https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-inducement-grant-to-chief-executive-officer-under
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer-2021-12-16
https://www.nasdaq.com/press-release/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressar-and-rocklatanr
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2021-11-09
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-third-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentation-at-the-ophthalmology-innovation-summit-2
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-positive-phase-3-topline-results-for-netarsudil
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentation-at-the-ophthalmology-innovation-summit-1
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentation-at-the-39th-annual-scientific-meeting-of
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-cantor-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-inc.-announces-the-appointment-of-interim-executive-chair-and
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-erik-pacyniak-ph.d.-d.a.b.t.-as
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-novel-dry-eye-product-candidate-ar-15512-trpm8
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-carolyn-mcauliffe-senior-director
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2021-09-07
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-michael-bradley-senior-director
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-h.c.-wainwright-ophthalmology-conference
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-second-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentation-at-the-ophthalmology-innovation-summit-0
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-leon-j.-atencia-director-of-regulatory
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-frank-estrada-ed.d.-as-director
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-raymond-james-human-health-innovation-0
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-completes-enrollment-of-its-first-phase-3-clinical-trial-of
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-raymond-james-human-health-innovation
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2021
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-first-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclandar-50-micrograms-ml
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-20th-annual-needham-virtual-healthcare
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-publication-of-peer-reviewed-paper-evaluating-the
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-presentation-at-the-ophthalmology-innovation-summit
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-oppenheimer-31st-annual-virtual
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2021-02
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-receives-european-commission-approval-for-roclandar-netarsudil
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclandar-in-the-european
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-the-stifel-2020-virtual-healthcare-conference
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-initiates-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist
https://www.nasdaq.com/press-release/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressar-and-rocklatanr
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-third-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-new-drug
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-successful-interim-90-day-topline-data-from-its-six
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-u.s.-food-and-drug-administration-approval-of-its-0
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2020-09
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-second-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-dexamethasone
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-appoints-peter-j.-mcdonnell-m.d.-to-the-companys-board-of
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-bank-of-america-securities-2020-healthcare
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-first-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-provides-2020-company-and-guidance-update-associated-with-covid
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-needham-virtual-healthcare-conference-2020-04
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-cowen-40th-annual-healthcare-conference-2020
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-nina-ohara-pharmd-m.b.a-as-director
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-ph.d.-as-vice
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-u.s.-food-and-drug-administration-approval-of-its
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-acceptance-for-review-of-the-roclandar-netarsudil-and
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-amine-sinmazisik-as-director-finance
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-submits-marketing-authorisation-application-for-roclandar
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-piper-jaffray-31st-annual-healthcare
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-receives-european-commission-approval-for-rhokiinsar-netarsudil
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-s.l.-to-advance
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-stifel-2019-healthcare-conference-2019-11-12
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-reports-third-quarter-2019-financial-results-updates-full-year
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-ophthalmic
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-announce-third-quarter-2019-financial-results-and-host
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-the-appointment-of-david-a.-hollander-m.d.-m.b.a.-as
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-completes-enrollment-in-the-phase-2-trial-of-ar-1105
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-charlene-e.-davis-esq.-as-vice
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-to-present-at-the-2019-cantor-fitzgerald-global-healthcare
https://www.nasdaq.com/press-release/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-rhokiinsar-in-the-european
